GVR Report cover RNA Targeting Small Molecule Drug Discovery Market Size, Share & Trends Report

RNA Targeting Small Molecule Drug Discovery Market Size, Share & Trends Analysis Report By Indication, By End-user, By Region, And Segment Forecasts, 2022 To 2030

  • Report ID: GVR453383
  • Number of Pages: 0
  • Format: Electronic (PDF)

Report Summary

The global RNA targeting small molecule drug discovery market is anticipated to reflect a considerable growth rate across the forecast period. RNA is considered a promising drug target, especially for cancer drugs, as compared to drugs targeting DNA and other proteins. Moreover, for small molecules, RNA-based drug targets have better bioavailability, absorption, and distribution characteristics. These are some of the major factors promoting the growth of RNA targeting small molecule drug discovery market.

With the increasing understanding of biological functions and the structure of RNA, more RNAs are recognized as important mediators in various diseases. However, the lack of information about RNA–small molecule interactions and RNA 3D structures limits the growth of RNA targeting small molecule drug discovery market.

In the recent years, a significant number of collaborations and partnerships have been made among the market players in the RNA targeting small molecule drug discovery market. For instance, in November 2021, Axcelead Drug Discovery Partners Inc., xFOREST Therapeutics Co., Ltd. and Kyowa Kirin Co., Ltd entered into an agreement to discover RNA-targeting drugs for small molecules. Such alliances in the future are likely to create opportunities for the growth of RNA targeting small molecule drug discovery market.

During the COVD-19 pandemic, researches were majorly focused on developing drugs for COVID-19. However, in the post pandemic period, the majority of the focus of researchers are developing innovative therapies for cancer, neurological disorders, and other diseases This is expected to support the growth of the RNA targeting small molecule drug discovery market in the post pandemic period.  

Based on end user, the pharmaceutical and biopharmaceutical companies segment has held a substantial share in the market. The increasing number of researches by these companies and the adoption of collaboration agreements among these companies for the development of drugs targeting RNA are the key factors contributing to the growth of the segment market.

North America held a significant share in the market in 2021. Technological advancements, presence of well-established research infrastructure, and higher investments in drug discovery R&D are the key factors promoting the RNA targeting small molecule drug discovery market in North America.

The key global industry players across the RNA targeting small molecule drug discovery market includes Nymirum Remix Therapeutics; Evotec AXXAM S.p.A.; Arrakis Therapeutics; Ribometrix; Santaris A/S; xFOREST Therapeutics Co., Ltd. Veritas In Silico Inc.; and HitGen Inc.

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.